Exchange: NASDAQ·Updated 07:30 PM EDT

PCRX News

News
all
press releases
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.read more...
Benzinga
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.read more...
Benzinga
More News
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira...
Business Wire
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Wall Street is abuzz with deal chatter as major healthcare, beverage, and oil companies eye significant deals in the coming weeks.
Stocktwits
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PR NewswireNEW YORK, Oct. 11, 2026NEW YORK, Oct. 11, 2026 /PRNewswire...
PR Newswire
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.read more...
Benzinga
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Zacks
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.
Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose 34.2% toread more...
Benzinga

Advertisement|Remove ads.